Pre-Open Stock Movers 10/21: (SIOX) (CROX) (XM) Higher; (ADMA) (IBM) (LRCX) Lower (more...)
Get Alerts SIOX Hot Sheet
Join SI Premium – FREE
Pre-Open Stock Movers:
Sio Gene Therapies Inc. (NASDAQ: SIOX) 14% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of Type I (early infantile-onset) and Type II (late infantile-onset and juvenile-onset) GM1 gangliosidosis. The Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Crocs (NASDAQ: CROX) 11.9% HIGHER; reported Q3 EPS of $2.47, $0.62 better than the analyst estimate of $1.85. Revenue for the quarter came in at $626 million versus the consensus estimate of $608.04 million.
Qualtrics International (NASDAQ: XM) 6.5% HIGHER; reported Q3 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $271.6 million versus the consensus estimate of $258.19 million. Qualtrics International sees Q4 2021 EPS of ($0.04)-($0.02), versus the consensus of ($0.04). Qualtrics International sees Q4 2021 revenue of $296-298 million, versus the consensus of $263.8 million. Qualtrics International sees FY2021 EPS of $0.02-$0.04, versus the consensus of ($0.01). Qualtrics International sees FY2021 revenue of $1.056-1.058 billion, versus the consensus of $1.01 billion.
ADMA Biologics, Inc. (Nasdaq: ADMA) 6.3% LOWER; announced that it intends to offer shares of its common stock for sale in an underwritten public offering.
IBM (NYSE: IBM) 5.3% LOWER; reported Q3 EPS of $2.52, $0.02 better than the analyst estimate of $2.50. Revenue for the quarter came in at $17.6 billion versus the consensus estimate of $17.77 billion.
Didi (NYSE: DIDI) 4.5% HIGHER; China's internet watchdog suggested Didi (NYSE: DIDI) and two other U.S.-listed firms explore listing in Hong Kong, as Beijing finishes its cybersecurity investigations into the companies, according to Dow Jones, citing people familiar with the matter.
HP Inc. (NYSE: HPQ) 3.6% HIGHER; FY22 EPS Tops Expectations, Raises Annual Dividend Approximately 29%
Lam Research (NASDAQ: LRCX) 3.2% LOWER; reported Q2 EPS of $8.36, $0.15 better than the analyst estimate of $8.21. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.32 billion. Lam Research sees Q3 2022 EPS of $7.87-$8.87, versus the consensus of $8.47. Lam Research sees Q3 2022 revenue of $4.15-4.65 billion, versus the consensus of $4.4 billion.
CSX Corp. (NASDAQ: CSX) 2.9% HIGHER; reported Q3 EPS of $0.43, $0.03 better than the analyst estimate of $0.40. Revenue for the quarter came in at $3.29 billion versus the consensus estimate of $3.15 billion.
Denny's Corporation (NASDAQ: DENN) 2.4% HIGHER; Truist Securities upgraded from Hold to Buy with a price target of $18.00 (from $17.00).
Tenet Healthcare (NYSE: THC) 2.2% HIGHER; reported Q3 EPS of $1.99, $1.03 better than the analyst estimate of $0.96. Revenue for the quarter came in at $4.89 billion versus the consensus estimate of $4.77 billion. Tenet Healthcare sees FY2021 EPS of $6.15-$6.38, versus the consensus of $5.57.
Canadian National (NYSE: CNI) 1.7% HIGHER; Activist Elliott Management has a large stake in the company and supports the CEO, Dow Jones reported.
Applied Materials, Inc. (NASDAQ: AMAT) 1.3% LOWER; down on LRCX's results.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NRx Pharmaceuticals (NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
- Johnson & Johnson (JNJ): FDA Advisers Unanimously Vote that carvykti Benefits Outweighing Risks as Earlier Treatment for a Type of Blood Cancer
- Daxor Corp. (DXR) CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Elliott Associates, Dividend, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!